Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| RADX | Radiopharm Theranostics | $11.18 | $6.92 | 162.44% | 30.4M | $40M | $3.50$16.25 |
| ARTV | Artiva Biotherapeutics | $4.98 | $1.68 | 50.91% | 20.7M | $81M | $1.47$11.55 |
| BENF | Beneficient | $6.24 | $1.44 | 29.89% | 575.3K | $533M | $1.75$12.48 |
| ASTI | Ascent Solar Technologies | $4.04 | $0.92 | 29.49% | 2.8M | $11M | $1.10$4.60 |
| KYTX | Kyverna Therapeutics | $11.20 | $2.42 | 27.56% | 405.2K | $385M | $1.78$13.64 |
| IMNM | Immunome | $23.53 | $3.96 | 20.23% | 323K | $1.8B | $5.15$25.31 |
| CPIX | Cumberland Pharmaceuticals | $3.04 | $0.51 | 20.16% | 333.6K | $38M | $1.85$7.25 |
| KXIN | Kaixin | $3.96 | $0.64 | 19.28% | 46.4K | $20M | $2.94$75.00 |
| SVRE | SaverOne 2014 | $3.51 | $0.51 | 17.00% | 1.2M | $2.2M | $2.31$190.75 |
| BDRX | Biodexa Pharmaceuticals Plc | $5.53 | $0.78 | 16.42% | 4.4M | $2.9M | $3.58$92.00 |
Related Articles
Featured Article
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
Leo Miller|Aug 29, 2024
Artiva's revolutionary cell therapies could be a patient lifeline and a goldmine for investors.
Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?
Alex Carchidi|Feb 25, 2024
The market's excited for these stocks, but there's no rush to buy them.
Down 80% in 1 Day, Is There Any Hope for FibroGen Stock?
Alex Carchidi|Jul 1, 2023
Its pipeline is looking thin, and it might hit another speed bump quite soon.
Advertisement
This Surprising Sector Is Sinking the Nasdaq Thursday
Dan Caplinger|Sep 1, 2022
It's not all about technology stocks.
What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?
Keith Speights|Jul 29, 2021
FDA approval of roxadustat seems unlikely.
Why Five Below, Sportsman's Warehouse, and Duluth Holdings All Moved by 10% Today
Reuben Gregg Brewer|Sep 3, 2020
Three retailers are putting up large early morning moves, two up and one down. Here's what you need to know.
FibroGen's Anemia Drug Goes to FDA for Review
Eric Volkman|Feb 12, 2020
A decision on Roxadustat should arrive by Dec. 20.
FibroGen Appoints Enrique Conterno as Its New CEO
Brian Orelli, PhD|Jan 6, 2020
The former Eli Lilly executive will be tasked with launching the biotech's anemia drug roxadustat.
![Enrique-Conterno[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F552569%2Fenrique-conterno1.jpg&w=384&op=resize)
What Retail Apocalypse? These 3 Chains Are Opening New Stores in 2020
Jon Quast|Jan 4, 2020
Five Below, Floor & Decor, and Duluth Holdings are valiantly defying the trend, but each faces a challenge while aggressively opening new locations this year.
Duluth Holdings Gains 25% on Earnings Surprise. Has the Stock Bottomed?
David Butler|Dec 6, 2019
The lifestyle brand has improved its finances since the painful first quarter. Going into the holiday season, this stock seems to have potential.
